Zhejiang Hisun Pharmaceutical Co., Ltd. provided earnings guidance for the year 2019. The company predicts to turn losses into gains in the net profit belonging to shareholders of the listed company in 2019 compared with the same period of the year before, with the net profit belonging to shareholders of the listed company to be between RMB 80 million and RMB 105 million (based on the disclosed statistics according to relevant regulations). The net loss belonging to shareholders of the listed company after excluding extraordinary profit and loss will be between RMB 2,510,000,000 and RMB 2,485,000,000.